Enabling medical innovation
The MDC-Verte Fund is dedicated to fostering innovation in the medical and biotech sectors, supporting early-stage companies developing technologies that improve healthcare outcomes.
Our investments
2024 portfolio
2024 was the Fund's first year of operations. We invested in the following companies:
Our largest investment, Next Step Robotics, has recently completed human trials with excellent results and is preparing for FDA clearance. They have already made several sales and are exploring international markets.
Promoted companies
Ready for investment
In the course of reviewing companies and working with inventors and entrepreneurs we often identify companies that merit consideration. We are reviewing those below for new or additional investment.
Current as of August 2026
| Company | Technology | Market | Stage | Raise | Legacy |
|---|---|---|---|---|---|
|
Next Step Robotics
|
Rehabilitation robotics for stroke recovery | $2B | Growth | Series A · $2.5M | UMB |
|
Sonosa Medical
|
Diagnosis and treatment of obstructive sleep apnea | $6B | Early | Series A · $2.5M | UMB |
|
Surgical Vision Systems
|
Innovative solutions for sterile processing | $6B | Early | Series Seed · $1.5M | UMB |
|
Modular Matter
|
Novel adaptive prosthesis | $2B | Early | Angel · $0.5M | MDC |
|
Connected Care Systems
|
Support for healthy aging and recovery at home | $2B | Developing | Angel · $0.5M | MDC |
|
MDC Studio
|
Engineering medical innovation | $10B | Growth | Series A · $10M | Various |
|
Advanced Surgical Design
|
Novel technologies for SI fusion | $2B | Developing | $100K startup funding | UMB |
|
IMERSE Surgical
|
Autonomous robotic suturing | TBD | Developing | Series Seed · $2M | JHU |
LivMedTech
|
First surgical platform to integrate common-path intraoperative OCT technology | $2B | Growth | Series Seed · $2.5M | JHU |
Digital Biosciences
|
SepsisDx — portable kit for sepsis classification | $2B | Developing | Series Seed · $1.5M | MDC |
Vascular Rescue
|
Wearable device for detection of hemorrhage and display of vital signs in the field | $1B | Developing | Angel · $0.5M | UMB |
Shuriken Medical
|
Novel feeding tube technology to reduce costs | $2B | Developing | Angel · $0.5M | JHU |
Aerea Medical
|
Novel technologies for airway restoration | $2B | Developing | Angel · $0.5M | UMB |
Our commitment
What we are building
MDC-Verte Ventures is committed to identifying and supporting high-potential companies that can drive innovation and growth in the biotech industry. We believe in the power of medical innovation to transform lives and are dedicated to enabling the success of our portfolio companies.
In addition to the companies listed above, we have identified unusually promising companies being considered for investment by the Fund. If you are interested in investing in MDC-Verte portfolio companies or in the promoted companies, please get in touch.
Investors in the Fund may also be eligible for the Maryland Biotechnology Investment Incentive Tax Credit, in addition to the capital gains deferral available through Qualified Opportunity Funds. See the FAQ for more.
Join us
We invite you to join us in supporting the next generation of medical and biotech innovators. Together we can make a significant impact on healthcare.